<DOC>
	<DOC>NCT00060489</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.</brief_summary>
	<brief_title>Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUELÂ®) in the Treatment of Patients With Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Written Informed Consent; Bipolar disorder with most recent episode depressed; Outpatient status Patients with a current Axis I disorder other than bipolar disorder within 6 months of screening; Patients whose current episode of depression exceeds 12 months or is less than 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bipolar Depression</keyword>
</DOC>